Investigation of Stem Cells in Human Lipoaspirate
Verified January 2015 by University of Nevada, Las Vegas
Information provided by (Responsible Party):
William A. Zamboni, M.D., University of Nevada, Las Vegas
First received: August 28, 2012
Last updated: January 8, 2015
Last verified: January 2015
The overall purpose of this study is to enhance identification and isolation of ADSCs and adipocytes, to find the optimum culturing conditions to increase growth and volume of grafts, and to study the effects of cryopreservation on ADSCs and adipocytes. Fat injections are used in aesthetic surgery but tend to disassemble over time. If the investigators can enhance growth and volume of fat in culture, the investigators could use fat grafts in reconstruction of cancer and traumatic injury defects with the patients own cultured fat cells and grafts.
||Observational Model: Case-Only
Time Perspective: Cross-Sectional
||Investigation of Adipose-Derived Stem Cells in Human Lipoaspirate
Primary Outcome Measures:
Secondary Outcome Measures:
- Percent of Apoptotic ADSCs [ Time Frame: Day of Surgery ] [ Designated as safety issue: No ]
Percent of apoptotic ADSCs will be measured on fresh samples and on refrigerated samples at 1, 2, 3, and 4 days refrigerated storage.
Biospecimen Retention: Samples Without DNA
Other Outcome Measures:
- Percent of Necrotic ADSCs [ Time Frame: Day of Surgery ] [ Designated as safety issue: No ]
Percent of necrotic ADSCs will be measured on fresh samples and on refrigerated samples at 1, 2, 3, and 4 days of refrigerated storage.
Cells from lipoaspirate maximum of 20 days
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||August 2018 (Final data collection date for primary outcome measure)
18-30 yrs, 31-50 yrs, 51-70 yrs
|Ages Eligible for Study:
||18 Years to 70 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- All adults (18-70 yrs) who have scheduled surgical lipectomy of the hips, abdomen, or thighs are prospective subjects for this study.
- Pregnant women will be excluded to protect the unborn child.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01677520
|University of Nevada School of Medicine Patient Care Center
|Las Vegas, Nevada, United States, 89102 |
|Contact: William A Zamboni, M.D. firstname.lastname@example.org |
|Contact: Karen Zamboni, BSRN 702-671-5118 email@example.com |
|Principal Investigator: William A Zamboni, M.D. |
University of Nevada, Las Vegas
||William A Zamboni, M.D.
||Wei Z Wang, M.D.
No publications provided
||William A. Zamboni, M.D., Professor and Chair Department of Surgery UNSOM, University of Nevada, Las Vegas
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 28, 2012
||January 8, 2015
||United States: Institutional Review Board
Keywords provided by University of Nevada, Las Vegas:
ClinicalTrials.gov processed this record on July 27, 2015
adipose-derived stem cells